The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies.


BACKGROUND Atypical hemolytic uremic syndrome (aHUS) is associated with significant mortality, progression to end-stage renal disease and recurrence post transplantation. The deficiency of CFHR plasma proteins and autoantibody-positive hemolytic uremic syndrome (DEAP-HUS) has a more favorable outcome. Guidelines suggest plasma therapy be initiated within 24… (More)
DOI: 10.5414/CN107777


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics